USFDA concludes inspection with no 483 observations at Divi's Labs Telangana facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-11-15 05:21 GMT | Update On 2025-11-15 05:21 GMT
Advertisement
Telangana: Divi's Labs has announced that the US Food and Drug Administration (USFDA) has concluded an inspection with no 483 observations at the Company's Unit-I facility at Lingojigudem Village, Choutuppal Mandal, Yadadri Bhuvanagiri district, Telangana.
The facility has been inspected by the USFDA from November 10, 2025 to November 14, 2025. This inspection was a general cGMP inspection by the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.